Infections

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Immune System Diseases

Nervous System Diseases

Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

Nutritional and Metabolic Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Communicable Diseases

Liver Diseases

Immunologic Deficiency Syndromes

Ataxia

Cerebellar Ataxia

Telangiectasis

Disease Susceptibility

Ataxia Telangiectasia

Gastrointestinal Diseases

Dyskinesias

Neurologic Manifestations

Cerebellar Diseases

Brain Diseases

Central Nervous System Diseases

Vascular Diseases

Spinocerebellar Ataxias

Spinocerebellar Degenerations

Syndrome

Neurocutaneous Syndromes

Genetic Diseases, Inborn

Primary Immunodeficiency Diseases

DNA Repair-Deficiency Disorders

Metabolic Diseases

Spinocerebellar Ataxia

All Drugs and Chemicals

Hematinics

Antibodies

Immunoglobulins

Immunoglobulin G

Liver Extracts

Immunoglobulins, Intravenous

A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution

* bioelectrical impedance Analysis
* blood draw
* transient elastography (FibroScan)
* ataxia score
* Five-Times-Sit-to-Stand Test

Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body

bioelectrical impedance analysis

Blood samples are taken from sober patients

blood draw

FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound

transient elastography (FibroScan)

Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb

ataxia score

The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series

Five-Times-Sit-to-Stand Test

Sandra Woelke, Dr.

Stefan Zielen, Prof. Dr.

Sandra Wölke, Dr.

Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus. Aim of the present clinical trial is to investigate frequency-, intensity- and duration of the infections as well as changes oft immune status, dimension of liver disease and tumor risk in patients with A-T, with and without immunoglobulin G substitution therapy. Transient elastography (FibroScan) will be performed in order to measure liver stiffness as an indication of fatty liver and liver fibrosis. A bioelectrical impedance analysis (BIA) is conducted to investigate the exact body composition. Ataxia Score is determined to define neurological problems. Every subject receives a diary to compile symptoms of infection.

Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus as shown in many trials. Additionally the patients suffer from a fatty liver with increased transaminases and have the risk for a cirrhosis of the liver and a hepatocellular carcinoma. It's known that the dimension of the liver disease affects susceptibility to infection. Nevertheless there are only a few studies treating this problem.

Despite the proof of the immunodeficiency polyvalent immunoglobulins (IgG) are not given regularly. Own observations show that in spite of the treatment with immunoglobulins the progression of a chronic destructive lung disease with development of bronchiectasis hardly can prohibited.

Up to now it isn't cleared if a substitution therapy with immunoglobulins reduces the susceptibility to infection. Therefore the aim oft the present clinical trial ist to explore frequency-, intensity, and duration oft the infections as well as changes oft the immune status, measure of liver disease and tumor risk in patients with A-T, with and without immunoglobulin therapy. The study includes five visits, which are performed in all A-T patients. Visit 1, 3, 5 are realized in the context of annual follow ups:

* To evaluate weight and length of all subjects
* To analyze the exact structure of single body compartments such as the lean mass, the water compartment or the fat compartment using bioelectrical impedance analysis
* To define the neurological status by ataxia score
* To get a detailed immune status, vaccination status and liver values as well as special tumor markers in blood
* To check the lung function using spirometry
* To measure liver stiffness using transient elastography (FibroScan)
* To compile any symptoms of infection by diary
* To investigate the ataxia status and physical condition by means of the Five-Times-Sit-to-Stand Test

Visit 2 and 4 are additionally conducted as study visits:

* To get a detailed immune status in blood
* To check the lung function using spirometry

Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia

Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia With and Without Substitution of Immunoglobulin G: a Prospective Observational Study

Evaluation of frequency, severity and intensity of infections in A-T patients with and without immunoglobulin G substitution

Evaluation of the degree of liver disease measured by liver enzymes and structural changes by transient elastography (Fibroscan) in A-T patients

Evaluation of tumor markers in A-T patients

Johann Wolfgang Goethe University Hospital

Prof. Dr. med. Stefan Zielen

Spots Global Cancer Trial Database for ataxia score

Every month we try and update this database with for ataxia score cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.